UC Irvine

UC Irvine Previously Published Works

Title

New Experimental and Computational Tools for Drug Discovery: From Chemistry to Biology. Metabolomics, Pharmacokinetics, and Medicinal Chemistry. Part - IV.

Permalink

<https://escholarship.org/uc/item/4tk8s07f>

Journal

Current topics in medicinal chemistry, 18(11)

ISSN

1568-0266

Authors

Fiandaca, Massimo S
Gonzalez-Dominguez, Raul
Gonzalez-Diaz, Humbert

Publication Date

2018

DOI

10.2174/156802661811180808095053

Peer reviewed

EDITORIAL

New Experimental and Computational Tools for Drug Discovery: From Chemistry to Biology. Metabolomics, Pharmacokinetics, and Medicinal Chemistry. Part - IV

Massimo S. Fiandaca^{a,b,c,d,*}, Raúl González-Domínguez^{e,f} and Humbert González-Díaz^{g,h,*}

Massimo S. Fiandaca

^aTranslational Laboratory and Biorepository, ^bDepartment of Neurology, ^cDepartment of Neurological Surgery, ^dDepartment of Anatomy & Neurobiology; University of California, Irvine School of Medicine; Irvine, California 92697, USA; ^eDepartment of Chemistry, Faculty of Experimental Sciences, University of Huelva, 21007 Huelva, Spain; ^fInternational Campus of Excellence CeIA3, University of Huelva, 21007, Spain; ^gDepartment of Organic Chemistry II, University of the Basque Country UPV/EHU, Leioa 48940, Biscay, Spain; ^hIKERBASQUE, Basque Foundation for Science, 48011 Bilbao, Biscay, Spain

Humbert González-Díaz

Raúl González-Domínguez

Enabling technologies like Computational Chemistry, Bioinformatics, Combinatorial Chemistry, Metabolomics, Proteomics (OMICS in general), *etc.*, are expected to speed up the discovery of more efficient and safer drugs in Medicinal Chemistry. Recently, this journal has launched a series of special issues focused on this topic. The title of this series of special issues is: New experimental and computational tools for drug discovery: From chemistry to biology. Four (1-4) special issues are currently available. In these issues, experts from around the world discuss the state-of-art and/or report new methodologies. The methodologies focus on organic synthesis of new lead compounds, the *in silico* screening of new lead compounds, computational discovery of drugs from natural compounds isolated from plants, the repurposing of known drugs, re-engineering of cost-effective medicines, nano-systems for drug release, *etc.* The present issue is entitled: New experimental and computational tools for drug discovery: From chemistry to biology. Part 4. Metabolomics, Pharmacokinetics, and Medicinal Chemistry. Part 4 is the continuation of the series and provides six papers focused on new technologies used in drug discovery, but this time with emphasis on Metabolomics, Pharmacokinetics, and Medicinal Chemistry. The papers included in Part 4 can be summarized as follows:

Gross *et al.* point out that metabolomics experiments generate a rich array of complex high-dimensional data. They suggest that this may, in part, account for past and more recent incomplete replications of previously specified biomarker panels, especially if not adequately considered. Herein, they identify common impediments challenging the analysis of raw, targeted Metabolomic abundance data and review methods that may remedy these issues, based on personal experiences and those of others. In doing so, they propose an analytical pipeline suitable for the pre-processing of data prior to downstream biomarker discovery.

González-Domínguez *et al.*, present work focused on intervention and observational trials as complementary tools in Metabolomics. The authors provide a review of the literature regarding the application of metabolomics in assessing metabolic alterations with diabetes, diabetic insulin resistance, and provide an oral glucose tolerance test case study to demonstrate the complementarity of observational and interventional study designs.

Kataria *et al.*, presented a work on the role of morin in Neurodegenerative Diseases (NDDs). NDDs are known to cause profound effects on families and patients, and a tremendous financial burden on the healthcare system of most populations worldwide. Morin, being a super antioxidant compound, may help prevent and mitigate such disorders by suppression of reactive oxygen species (ROS) and through the inhibition of multiple additional targets. In this review, the authors discuss various neuropathological conditions and their specific target sites that may be relevant to morin's neurobiological mechanisms.

Bueso-Bordils *et al.*, focused on obtaining microbiological and pharmacokinetic predictive equations. They reviewed the state-of-art in the area and also reported a new study. Multi-linear regression (MLR) analysis was carried out in order to accurately predict physicochemical properties and biological activities on a group of antibacterial quinolones by means of a set of structural descriptors called topological indices. The aim of this work included developing prediction equations for such properties, after reviewing the relevant literature on antibacterial quinolones.

De Sousa Eduardo *et al.*, focus on the requirement of research related to new antimicrobial agents, as increasing numbers of microorganisms expressing antibiotic-resistance are emerging. In this paper, the authors review the topic and also provide veri-

fication for the activity of a phytoconstituent against *Escherichia coli* strains ATCC 25922 and *Staphylococcus aureus* ATCC 25923. The authors recommend further investigations, utilizing different methodologies assessing whether (+) - α -pinene may provide an effective compound in future antimicrobial therapy.

Srivastava *et al.*, focused on the inhibition of biofilm and virulence factors associated with *Candida albicans* by the partially purified secondary metabolites of *Streptomyces chrestomyceticus* strain ADP4. Despite several advancements in antifungal drug discovery, fungal diseases, such as Invasive Candidiasis (IC), remain associated with inordinately high rates of morbidity and mortality worldwide. In this paper, chemical profiling indicates that ADP4 secondary metabolites contained potentially beneficial alkaloids, flavonoids, polyphenols, terpenoids and triterpenes. The authors also report other experimental and computational findings.

ACKNOWLEDGEMENTS

We would like to thank Allen B. Reitz, the Editor in Chief, Ambreen Irshad, Associate Editor, and all the contributing authors and reviewers for their support and contributions to the issue. G.D.H. acknowledges partial financial support from the grants of MINECO (CTQ2016-74881-P)-2017-2019 and Basque Government (IT1045-16)-2016-2021.

Massimo S. Fiandaca

(Guest Editor)

Current Topics in Medicinal Chemistry

Departments of Neurology, Neurological Surgery, and

Anatomy & Neurobiology

University of California, Irvine School of Medicine

Irvine, CA 92697

USA

E-mail: mfiandac@uci.edu

Humbert González-Díaz

(Europe Editor)

Current Topics in Medicinal Chemistry

Department of Organic Chemistry II

University of the Basque Country UPV/EHU

Leioa 48940, Biscay, Spain

IKERBASQUE, Basque Foundation for Science

48011 Bilbao, Biscay

Spain

E-mail: humberto.gonzalezdiaz@ehu.es

Raúl González-Domínguez

(Guest Editor)

Current Topics in Medicinal Chemistry

Department of Chemistry

Faculty of Experimental Sciences

University of Huelva, 21007 Huelva, Spain

International Campus of Excellence CeIA3,

University of Huelva, 21007 Huelva

Spain

E-mail: raul.gonzalez@dqcm.uhu.es